BACKGROUND: There is an ongoing debate as to whether combined antiretroviral treatment (cART) during pregnancy is an independent risk factor for prematurity in HIV-1-infected women. OBJECTIVE: The aim of the study was to examine (1) crude effects of different ART regimens on prematurity, (2) the association between duration of cART and duration of pregnancy, and (3) the role of possibly confounding risk factors for prematurity. METHOD: We analysed data from 1180 pregnancies prospectively collected by the Swiss Mother and Child HIV Cohort Study (MoCHiV) and the Swiss HIV Cohort Study (SHCS). RESULTS: Odds ratios for prematurity in women receiving mono/dual therapy and cART were 1.8 [95% confidence interval (CI) 0.85-3.6] and 2.5 (95% CI 1.4-4.3) compared with women not receiving ART during pregnancy (P=0.004). In a subgroup of 365 pregnancies with comprehensive information on maternal clinical, demographic and lifestyle characteristics, there was no indication that maternal viral load, age, ethnicity or history of injecting drug use affected prematurity rates associated with the use of cART. Duration of cART before delivery was also not associated with duration of pregnancy. CONCLUSION: Our study indicates that confounding by maternal risk factors or duration of cART exposure is not a likely explanation for the effects of ART on prematurity in HIV-1-infected women.
BACKGROUND: There is an ongoing debate as to whether combined antiretroviral treatment (cART) during pregnancy is an independent risk factor for prematurity in HIV-1-infectedwomen. OBJECTIVE: The aim of the study was to examine (1) crude effects of different ART regimens on prematurity, (2) the association between duration of cART and duration of pregnancy, and (3) the role of possibly confounding risk factors for prematurity. METHOD: We analysed data from 1180 pregnancies prospectively collected by the Swiss Mother and Child HIV Cohort Study (MoCHiV) and the Swiss HIV Cohort Study (SHCS). RESULTS: Odds ratios for prematurity in women receiving mono/dual therapy and cART were 1.8 [95% confidence interval (CI) 0.85-3.6] and 2.5 (95% CI 1.4-4.3) compared with women not receiving ART during pregnancy (P=0.004). In a subgroup of 365 pregnancies with comprehensive information on maternal clinical, demographic and lifestyle characteristics, there was no indication that maternal viral load, age, ethnicity or history of injecting drug use affected prematurity rates associated with the use of cART. Duration of cART before delivery was also not associated with duration of pregnancy. CONCLUSION: Our study indicates that confounding by maternal risk factors or duration of cART exposure is not a likely explanation for the effects of ART on prematurity in HIV-1-infectedwomen.
Authors: D Heather Watts; Paige L Williams; Deborah Kacanek; Raymond Griner; Kenneth Rich; Rohan Hazra; Lynne M Mofenson; Hermann A Mendez Journal: J Infect Dis Date: 2012-11-29 Impact factor: 5.226
Authors: Amina P Alio; Alfred K Mbah; Krupa Shah; Euna M August; Sharon Dejoy; Korede Adegoke; Phillip J Marty; Hamisu M Salihu; Muktar H Aliyu Journal: Am J Mens Health Date: 2013-08-02
Authors: Catherine A Koss; Paul Natureeba; Albert Plenty; Flavia Luwedde; Julia Mwesigwa; Veronica Ades; Edwin D Charlebois; Tamara D Clark; Jane Achan; Theodore Ruel; Bridget Nzarubara; Moses R Kamya; Diane V Havlir; Deborah Cohan Journal: J Acquir Immune Defic Syndr Date: 2014-10-01 Impact factor: 3.731
Authors: Susie E Huntington; Claire Thorne; Loveleen K Bansi; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: AIDS Date: 2013-01-02 Impact factor: 4.177